Lundbeck Names New President and CEOBy
Deborah Dunsire, MD, has been named as the new President and Chief Executive Officer (CEO) of H. Lundbeck A/S, a Valby, Denmark-based pharmaceutical company, effective September 1, 2018. She will succeed Anders Götzsche, currently the company’s Chief Financial Officer (CFO), who has served as Lundbeck’s interim CEO since Kåre Schultz, former President and CEO of Lundbeck, left the company in September 2017 and became President and CEO of Teva Pharmaceutical Industries in November 2017.
Dr. Dunsire is trained as a medical doctor and brings more than 30 years of clinical, commercial, and international management experience from the biotechnology and pharmaceutical industry, primarily in the fields of oncology and central nervous system disorders. Her professional and executive experience includes positions as President and CEO of XTuit Pharmaceuticals, a Waltham, Massachusetts-based biopharmaceutical company, Forum Pharmaceuticals, a Waltham, Massachusetts-based pharmaceutical company, and Millennium Pharmaceuticals, a Cambridge, Massachusetts-based biopharmaceutical company that was acquired by Takeda Pharmaceutical Company in 2008.
Götzsche will resume his position as CFO for the company, effective September 1, 2018.